secwatch.observer — SEC 8-K summary
======================================

Issuer:     STAAR SURGICAL CO (STAA)
CIK:        0000718937
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002738
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STAAR Surgical prelim Q4 net sales ~$76.5M, ICL sales +22%; FY2024 outlook $335-340M
--------------------------------------------------------------------------------

- Preliminary FY2023 net sales ~$322.5M (+13% YoY); Q4 net sales ~$76.5M (+19% YoY).
- Global ICL sales up 22% in Q4 (APAC +26%) and 18% for FY2023; ICL unit growth outpaced refractive industry by 26 points in 2023.
- FY2024 net sales guidance of $335-340M, implying ~10% ICL growth in both China and U.S.; GAAP operating margin expected at least breakeven.
- Cash and investments ~$230M, up ~$28M from Q3; accounts receivable ~$90M.
- Full FY2023 results to be reported on or about Feb 21, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/718937/000095017024002738/0000950170-24-002738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/718937/000095017024002738/staa-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer